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Abstract
Background: Neutrophils are involved in thrombus formation. We investigated whether specific features of neutrophil
activation characterize patients with acute coronary syndromes (ACS) compared to stable angina and to systemic
inflammatory diseases.
Methods and Findings: The myeloperoxidase (MPO) content of circulating neutrophils was determined by flow cytometry
in 330 subjects: 69 consecutive patients with acute coronary syndromes (ACS), 69 with chronic stable angina (CSA), 50 with
inflammation due to either non-infectious (acute bone fracture), infectious (sepsis) or autoimmune diseases (small and large
vessel systemic vasculitis, rheumatoid arthritis). Four patients have also been studied before and after sterile acute injury of
the myocardium (septal alcoholization). One hundred thirty-eight healthy donors were studied in parallel. Neutrophils with
normal MPO content were 96% in controls, .92% in patients undergoing septal alcoholization, 91% in CSA patients, but
only 35 and 30% in unstable angina and AMI (STEMI and NSTEMI) patients, compared to 80%, 75% and 2% of patients with
giant cell arteritis, acute bone fracture and severe sepsis. In addition, in 32/33 STEMI and 9/21 NSTEMI patients respectively,
20% and 12% of neutrophils had complete MPO depletion during the first 4 hours after the onset of symptoms, a feature
not observed in any other group of patients. MPO depletion was associated with platelet activation, indicated by P-selectin
expression, activation and transactivation of leukocyte b2-integrins and formation of platelet neutrophil and -monocyte
aggregates. The injection of activated platelets in mice produced transient, P-selectin dependent, complete MPO depletion
in about 50% of neutrophils.
Conclusions: ACS are characterized by intense neutrophil activation, like other systemic inflammatory syndromes. In the
very early phase of acute myocardial infarction only a subpopulation of neutrophils is massively activated, possibly via
platelet-P selectin interactions. This paroxysmal activation could contribute to occlusive thrombosis.
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Introduction
Platelet and endothelial activation, associated with plaque
instability, are important mechanisms in the pathogenesis of acute
coronary syndromes (ACS) [1–5]. Activated platelets and endo-
thelium interact with circulating leukocytes [6–16], which are also
activated in ACS generating a positive feed-back loop.
Activated platelets and neutrophils appear in the peripheral
circulation after the onset of acute symptoms of infarction, but
gradually disappear during the subsequent hours [1,10,11,17] at
variance with platelet-monocyte heterotypic aggregates, which
persist longer [1,17]. Neutrophils also represent the major cellular
component of coronary thrombi [2,4,13,18,19] and their activa-
tion is associated with massive myeloperoxidase (MPO) release
[3,10,11,20] [21–22]. In turn the peak concentration of circulating
MPO is reached in the very early hours after infarction [3] and
MPO is found in unstable coronary plaques at post mortem
[2,4,13,19].
Given the short life of circulating neutrophils the release of their
MPO content can only reflect the effects of stimuli active during
the previous 6–8 hours of their life time. Thus, measurement of
neutrophil MPO content at different times after the onset of
symptoms could provide information on the time-course as well as
clues on distinctive features of inflammatory stimuli associated
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e39484with coronary instability. We have studied neutrophil MPO
content and its relation to platelet and monocyte activation in
patients with segment T elevation myocardial infarction (STEMI),
with non elevation myocardial infarction (NSTEMI) and with
unstable angina, sampled before any therapeutic intervention. As
controls, we studied patients with chronic stable angina (CSA)
before and after coronary angioplasty. In addition, for compar-
ison, we have studied patients with well established inflammatory
conditions: Giant Cell Arteritis, Polymyalgia Rheumatica, ANCA-
associated small-vessel vasculitis, rheumatoid arthritis, severe
sepsis, and acute traumatic bone fractures.
We have observed a large reduction of the average MPO
content in most patients but not in matched healthy controls or in
subject with CSA. In addition, we have identified a distinctive
feature of neutrophil activation in the very early hours after acute
myocardial infarction, reflecting a paroxysmal response to an
intense, short lasting trigger. Platelet P-selectin expression was
correlated with neutrophil activation, which in turn may
contribute to thrombus formation [15,16,23].
Materials and Methods
Patients and Controls
Patients and healthy donors (330 consecutive subjects) were
studied in blind. We studied 69 patients with acute coronary
syndromes before any therapeutic intervention: 54 with acute
myocardial infarction (AMI) (34 with STEMI and 20 with
NSTEMI), and 15 patients with unstable angina, studied less
than 12 hours (mean6SD 4.0 hours 630 min) from the onset of
symptoms. Unstable angina was defined as typical chest pain at
rest without elevation of creatine kinase or troponin I. AMI was
defined on the basis of chest pain at rest, ECG recording and
elevation of creatine kinase or troponin I. STEMI patients were all
those that had electrocardiography evidence of at least 2 mm in at
least 2 consecutive leads of ST segment elevation. From each
patient, clinical data were obtained, including age, sex, hypercho-
lesterolemia (total plasma cholesterol concentration .200 mg/dl
or ongoing lipid-lowering drug therapy), hypertension (history of
elevated blood pressure requiring antihypertensive therapy),
diabetes mellitus (history of diabetes or fasting plasma glucose
.126 or .200 mg/dl 2 h after a meal), active smoking (.5
cigarettes daily), and overweight/obesity (body mass index
.25 kg/m
2), C-reactive protein (CRP) and erythrocyte sedimen-
tation rate (ESR). To analyze the time course of neutrophil
activation in acute coronary syndromes, 36 AMI patients and 10
patients with unstable angina were again studied at 24, 36 and 48
hours after Percutaneous Coronary Intervention (PCI). We also
studied 69 patients with chronic stable angina (CSA) at the time of
coronary angiography: 15 of them were re-investigated 4 hours
after PCI. All CSA patients had evidence of myocardial ischemia
during stress tests or of angina recurrence. PCI was performed in
case of: i) angiographic evidence of critical stenosis (.75%) or ii)
lesions with stenosis ,75% but characterized by a reduced
myocardial fractional flow reserve (cut-off ,0.75). Four patients
with hypertrophic obstructive cardiomyopathy were studied before
and four hours after absolute ethanol had been introduced into a
major septal artery to create a controlled septal infarction [24]. We
also studied five patients with bone fractures, seven patients with
severe sepsis, 11 patients with ANCA-associated small-vessel
vasculitis, eight patients with polymyalgia rheumatica, eight
patients with giant cell arteritis and eleven patients with
rheumatoid arthritis previous any treatment, classified according
to the American Rheumatism Association 1987 revised criteria
[25]. Patient clinical and demographic characteristics are summa-
rized in Tables 1, 2 and 3. In parallel, 138 healthy donors were
also studied (Table S1). In all cases exclusion criteria were: age
,18 years, serum creatinine .2 mg/dL, anemia and history of
cancer. All patients and controls signed an informed consent form
(see ethics statement).
Blood Sampling and Processing
Venous blood was obtained using a 19-gauge butterfly. Blood
was first drawn in a vacutainer tube to obtain serum followed by
the collection of 3 mL into a tube containing sodium citrate and a
cocktail of antiproteases (sodium EDTA, N-ethylmaleimide and
aprotinin) used to study the neutrophil MPO content and cellular
markers of activation by flow cytometry and confocal microscopy
as previously described [9,10,11,26]. All determinations were
performed in blind for the laboratory operators.
Reagents and Monoclonal Antibodies (mAbs)
Thrombofix, mAbs against human CD14 (clone RMO52),
human CD42a (platelet glycoprotein Ib, clone SZ2), human
CD45 (clone J33), CD61 (platelet glycoprotein IIIa, clone
SZ21), human CD66b (clone 80H3), and human MPO (clone
CLB-MPO-1) and the isotype-matched control mAb (clone
679.1Mc7) were from Instrumentation Laboratories (Milan,
Italy). FACs Lysing Solution mAbs against human P-selectin
Table 1. Characteristics of patients with coronary artery
diseases.
UA
n 15
AMI
n 54
CSA
n 69
Age, median (range) 61.5 (48–70) 61.7 (42–71) 60.1 (45–72)
Sex: M/F 12/3 47/7 44/15
CRP (mg/L) 4.060.3 4.860.8 1.260.3
ESR (mm/h) 2.160.4 15.861.6 2.360.3
Initial troponin I 0.260.1 1.260.2 n.a.
Peak troponin I n.a. 30.666.6 n.a.
Risk Factors
Cholesterol (mg/dL) 198.1610.3 203.067.11 193.0611.7
Diabetes 2/15 4/54 11/69
Hypertension 3 24 35
Current smoking 5 24 9
Obesity 3 6 4
N6 of involved coronary arteries: % patients
0 25% 12% 0%
1 25% 36% 10%
2 25% 32% 30%
3 25% 20% 60%
History
Previous AMI 2 0 17
Previous CABG 0 0 15
Previous PCI 0 0 23
Ejection fraction 56.764.1 47.969.3 54.466.8
Aspirin 15 25 69
Statins 5 19 41
Demographic and clinical data are referred to the time of blood sample
collection. CABG: Coronary Artery Bypass Graft. PCI: Percutaneous Coronary
Intervention.
Neutrophil Activation in AMI
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mouse CD61 (clone 2C9.G2), mouse CD14 (clone mC5-3) and
mouse CD45 (clone 30-F11) and appropriate isotypic control
mAbs were from Becton Dickinson (Milan, Italy). Isotype-
matched control were from Beckman Coulter (Milan, Italy);
mAbs against mouse neutrophils (clone 7/4), against mouse
MPO, against human MRP8/14 (clone 27E10) and its isotype
control were from Abcam Inc (Milan, Italy). The Zenon IgG
Labeling kits were from Invitrogen, (Milan, Italy). The FIX &
PERM kit was from Caltag (Turin, Italy). mAb 327c recognizes
an activation-dependent epitope in the I domain of the ß2
integrin subunit [27].
Flow Cytometry
Measurement of the neutrophil MPO content was performed as
described [9,10,11,26]. Briefly, whole blood samples were labeled
with mAbs against CD45, CD14 and CD66b, treated with by
FACs lysing solution, washed, resuspended in cold PBS, fixed and
permeabilized by Fix&Perm and labeled with mAb against MPO,
or the specific isotypic control. Neutrophils were identified by their
Table 2. Characteristics of patients with systemic inflammatory syndromes.
ANCA-associated small-vessel
vasculitis Giant Cell Arteritis
Polymyalgia
rheumatica Rheumatoid Arthritis
n 11 8 8 11
Sex M/F 9/11 2/6 2/6 4/7
Age (years) 49.5 (36–78) 71 (63–87) 70 (64–81) 59.5 (32–78)
Disease duration (months) 108611.1 10.562.2 29.466.2 23.968.9
CRP (mg/L) 17.865.5 11.562.5 13.363.1 32.2613.6
ESR (mm/h) 37.1611.3 32.864.1 40.468.2 44.6611.4
Disease activity (active n, %)
" 8 (72.7%) 6 (75%) 5 (62.5%) 8 (72.7%)
Prednisone (mg/day) 19.165.1 12.962.5 4.161.8 1.360.7
Immnosuppressive drugs (n) Cyclophosphamide (1)
Rituximab (1)
Azathioprine (2) Methotrexate (1) –
Organ involvement (n) ** ENT (11)
1ung nodules (5)
PNS (5)
Nephritis (4)
Arthritis (4)
Cranial nerve neuritis (1)
Orchitis (1)
Headache (4)
Myalgias (1)
Aortitis (1)
Past optic nerve ischemia (2)
Myalgias (8) 11 Arthritis (11)
Bone erosions (5)
Lung nodules (1)
Demographic and clinical data are referred to the time of blood sample collection. If not otherwpone.0039484.g004.tifise specified, means6SEM are shown.
**number of patients with disease-related organ involvement. ENT = ear, nose, throat; PNS = peripheral nervous system.
"number (%) of patients with active disease (as assessed by the Rheumatologist on the basis of symptoms, inflammatory markers and, when available for the specific
disease, disease activity scores).
doi:10.1371/journal.pone.0039484.t002
Table 3. Characteristics of septic patients.
Patient/
sex/age
(years) primary infection
cultures (microorganism/
material)
Shock
(lactate) **
Organ
Involvemen
t (present)
" CRP (mg/l)
organ
involvement
(following)
" outcome ***
1/F/60 pneumonia S. aureus/blood + (3.52) Res, Ren, Hep 277 (DIC) A
2/F/69 diverticulitis Staphylococcus spp/blood – – 473 – A
3/F/86 colitis C. difficile/fecies – – 32.9 – A
4/M/63 bilateral pneumonia S. marcescens/bronchoalveolar
fluid
+ (2.57) Ren 204 Hep, DIC D
5/F/81 pneumonia S. aureus/bronchoalveolar
fluid + blood
– Res, Ren 141 – D
6/F/79 urinary tract infection P.aeruginosa/
blood
+ (2.90) Ren, Hep 225 – A
7/M/82 aspiration pneumonia E. coli/bronchoaspirate +
blood
+ Resp 220 (DIC) D
When not otherwise specified, demographic and clinical data are referred to the time of blood sample collection, and means 6 SEM values are shown for each group;
+ : present; 2 : absent;
**septic shock: when present, lactate concentration (mmol/L) is shown in brackets; " involved organs at the time of blood sample collection (present) or additional
organ involvement in the following 3 days (following); Res: respiratory failure; Ren: renal failure, Hep: hepatic failure; DIC = Disseminated Intravascular Coagulation;
***outcome A: alive, D: dead.
doi:10.1371/journal.pone.0039484.t003
Neutrophil Activation in AMI
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+ population,
comprising .99% CD66b
+ and ,1% CD14
+ events. The normal
range of the neutrophil MPO content was defined on the basis of
the results obtained in 50 healthy subjects. In order to establish the
background level of MPO-associated fluorescence after complete
MPO depletion, the neutrophil MPO content was also assessed
after stimulation of whole blood samples with fMLP (0.5 mM) in
the presence of cytochalasin B (2.5 mg/mL) to induce the full
release of neutrophil azurophilic granules content [28]. We used
the intermediate range of MPO-associated MFI to define
neutrophils with low MPO content. (Figure S1). Platelet
leukocyte heterotypic aggregates, platelet P-selectin, leukocyte ß2
upregulation and transactivation as well as leukocyte MRP8/14
expression were measured as previously described [9,10,11,26].
Analysis of samples was with a FC500, Beckman-Coulter.
Animal Model
Whole blood from female C57BL/6N mice (wild type) or from
C57BL/6-P-selectin (P-sel
2/2) was obtained, processed and
activated as described [10,26]. Platelets were injected in the tail
vein of wild type mice. After 1, 2, 3, and 24 hours blood was
obtained from the tail. The neutrophil MPO content and platelet-
neutrophil heterotypic were determined by flow cytometry as
described [10,26].
Results
Circulating Neutrophil Degranulation
The neutrophil MPO content was assessed by flow cytometry
and by confocal microscopy in whole blood samples fixed and
labeled without any further manipulation. The normal range of
neutrophil MPO content, preliminarily defined in our laboratory
on the basis of the results obtained on 50 healthy subjects, ranged
between 98 and 203 arbitrary units of mean fluorescence intensity
(MFI) detected within the neutrophil (CD66b
+) population.
Background signal (after complete neutrophil MPO depletion by
stimulation of whole blood samples with fMLP) was to 8–22 MFI.
Thus the 23–97 MFI range was used to define neutrophils with
low MPO content (Figure S1).
The average neutrophil MPO content in healthy donors
(149.363.4 MFI) was stable: it did not substantially change with
age (age range 20–80 years) or gender (Table S1). The MPO
content in contrast was dramatically reduced in patients with ACS
(Table 4, Figure 1 and Figure S1), but it was unaffected, either
before or after PCI, in patients with CSA who had a greater
burden of coronary atherosclerosis than ACS patients (Table 1
and Table 4).
Neutrophils from STEMI patients had a significantly greater
reduction of the average MPO content compared to NSTEMI
patients and patients with unstable angina (56.165.8 vs 73.2610.4
and vs 91.7612.0 MFI, p,0.005). Interestingly, a trimodal
distribution of neutrophil MPO was found in all but one STEMI
patients: complete depletion in 21.565.4% of neutrophils (7.561
MFI), reduced content in 46.567% of neutrophils (51.363.7
MFI), and normal content in 30.667.1% of neutrophils
(139.6614.4 MFI) (Figure 1, panels A-D, Table 4).
The simultaneous occurrence of three different sub-populations
of neutrophils was confirmed by confocal microscopy (Figure 1,
panels B). Nine of 21 NSTEMI patients also had a trimodal
pattern of MPO expression. By contrast, neutrophils from patients
Table 4. Neutrophil myeloperoxidase (MPO) content.
n
Neutrophils
count
(610
3/mL)
Average MPO
content
(MFI)
MPO depletion
(% neutrophils)
Low
MPO content
(% neutrophils)
Normal
MPO content
(% neutrophils)
Trimodal MPO
content
(N6/total)
Healthy volunteers 138 3,660,8 149.3614.0 ,11 . 2 60.9 96.461.4 0/138
ACS
STEMI 33 9.260.6
1 56.165.8
1 21.565.4
1 45.667.2
1 30.667.1
1 32/33
NSTEMI 21 7.960.5
1 73.2610.4
1 11.864.1
1 56.966.5
1 29.966.2
1 9/21
UA 15 5.260.5
" 91.7612.0* ,1 60.066.2
1 36.5611.4
1 0/15
CSA
before PCI 69 4.062.8 134.1626.9 ,15 . 8 61.6* 91.264.7 0/54
after PCI 15 3.860.3 133.168.7 ,1 11.864.0
" 87.565.7 0/15
Septal Alcholization
before 4 3.660.7 131.3611.8 ,14 . 3 61.8 92.862.8 0/4
after 4 4.860.2 170.8610.9 ,12 . 5 61.3 97.261.8 0/4
Acute traumatic bone
fracture
5 12.860.3
1 116.2612.8 ,1 23.969.1
1 75.269.3* 0/5
ANCA-associated small-
vessel vasculitis
11 7.861.4
1 87.969.9
" ,1 59.668.3
1 36.568.4
1 0/11
Rheumatoid Arthritis 11 7.660.9
1 80.0611.7
" ,1 74.569.1
1 19.163.8
1 0/11
Giant Cell Arteritis 8 5.160.9* 84.4618.6
" ,1 16.0611.3
" 80.468.6 0/8
Polymyalgia Rheumatica 8 5.761.5* 49.6614.9
1 ,1 63.2619.3
1 22.367.1
1 0/8
Sepsis 7 22.264.4
1 61.968.8
1 ,1 97.063.5
1 2.062.1
1 0/7
MPO= myeloperoxidase. MFI: mean fluorescence intensity revealed within neutrophils (CD45+, CD66b+, CD142 cells). ACS: acute coronary syndromes. STEMI: segment
T elevated myocardial infarction. NSTEMI: no STEMI. UA: unstable angina. ANCA: anti neutrophils cytoplasmatic antigens. Statistically different from the healthy
volunteers *=P,0.05;
"=P,0.01 and
1=P,0.001.
doi:10.1371/journal.pone.0039484.t004
Neutrophil Activation in AMI
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expression of MPO (Table 4). Neutrophil degranulation was
significantly associated with up-regulation and transactivation of
the leukocyte ß2 integrin (CD11b/CD18) Mac-1 (Table 5).
CD16 expression is reduced or absent in apoptotic neutrophils
([29,30,31]).The possibility that complete MPO depletion ob-
served in AMI patients was due to neutrophil apoptosis was ruled
out by the observation that 94.161.8% of neutrophils with
complete MPO depletion in 15 consecutive AMI patients had a
normal expression of CD16 (859.1622.2 MFI) compared to that
of healthy matched controls (96.661.3%, 855.2615.4 MFI). At
variance, the subpopulation of neutrophils with normal MPO
content was positive for MRP8.14, possibly reflecting its recent
release into the bloodstream (Table 5).
Figure 1. Heterogeneity of myeloperoxidase content in circulating neutrophils from patients with acute myocardial infarction is
associated to platelet adhesion and activation. Intracellular MPO content in circulating neutrophils and platelet-neutrophil heterotypic
aggregates were evaluated in whole blood samples by four-color flow cytometry. Venous blood samples were obtained within the first 6 hours of
onset of symptoms. For confocal determinations, monoclonal antibodies against MPO were labeled with Alexa Fluor 488 (green) and against platelet
glycoprotein Ib with Alexa Fluor 546 (red). Hoechst (blue) was used for counterstaining of nuclei. Panel A. Representative confocal images illustrate
the MPO (green) content observed in circulating neutrophils of a patient with chronic stable angina. Panel B. Representative confocal images illustrate
the heterogeneity in the MPO (green) content observed in circulating neutrophils of a patient with acute myocardial infarction. Panel C-D. The
cytofluorimetric histogram shows the trimodal pattern MPO-associated distribution (black) in AMI but not in CSA, vs isotype control (white). Panel E:
confocal images of neutrophils with complete MPO depletion, low or normal MPO content. Results are the mean value 6 SEM of heterotypic
aggregates observed in each neutrophil subpopulation. Panel F: confocal microscopy of aggregates between platelet (red) and degranulated
neutrophils from a representative patient with AMI. Panel H. Correlation analysis indicates the association between platelet activation and neutrophil
myeloperoxidase content in patients with AMI: platelet P-selectin expression (% of CD61
+ cells, y axis) are plotted against the neutrophil intracellular
MPO content (MFI-within CD66b
+ cells, x axis; R=0.6, P,0.0001).
doi:10.1371/journal.pone.0039484.g001
Neutrophil Activation in AMI
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The percentage of neutrophils with a complete MPO depletion
was greatest in STEMI patients studied within 4 hours,
intermediate in those studied within 4–8 hours and lower in
samples collected 8–12 hours after the onset of symptoms (in all
cases prior to any treatment) (Figure 2). The average neutrophil
MPO content returned to normal values within 24–36 hours
(Figure 2).
Neutrophil activation was associated with monocyte activation,
as indicated by CD11b/CD18 up-regulation and transactivation
(Table 5). In all ACS patients a significant increase of platelet-
leukocyte (neutrophils and monocytes) heterotypic aggregates was
observed (Table 5, Figure 1, panels E-F and Figure 2). This
was maximal for neutrophils in samples taken early after the onset
of symptoms and disappeared within 24 hours (Figure 2, panel
F). Monocyte activation persisted after 48 hour, possibly because
of monocyte longer life span (Figure 2, panel G). Circulating
platelets were also activated, as indicated by the up-regulation of
surface P-selectin (Table 5). The time course of platelet activation
was similar to that of neutrophils (Figure 2, panel E).
Neutrophil Activation in Systemic Inflammatory
Conditions
To investigate whether the trimodal pattern of MPO expression
observed in the very early phases of STEMI was also present in
other systemic inflammatory syndromes, we studied conditions of
leukocyte activation associated with microbial infection (sepsis) or
with self-sustained systemic inflammation (rheumatoid arthritis,
ANCA-associated small-vessel vasculitis, polymyalgia rheumatica
and giant cell arteritis) (Tables 2 and 3). A reduced neutrophil
MPO content was observed in all these clinical conditions. The
trimodal pattern of MPO expression observed in AMI patients was
not detectable in any of the other conditions, regardless of: i)
increased peripheral neutrophil count in patients with acute
traumatic bone fracture (12.860.3 neutrophils/mL) and sepsis
(22.264.4 neutrophils/mL); ii) the presence of ANCA, known to
amplify the activation of neutrophils [12], and iii) the massive
elevation in inflammatory markers of patients with giant cell
arteritis, polymyalgia rheumatica or rheumatoid arthritis
(Table 4). A normal MPO content was observed in the four
patients undergoing septal alcoholization; taken together with the
normal MPO content observed in patients with bone fracture
these data strongly suggest that tissue necrosis per se is not
responsible for the trimodal pattern of MPO expression observed
in AMI patients (Table 4).
Neutrophils MPO Depletion and Platelet Activation
As platelet activation has been associated to neutrophil
degranulation [10,11,28] we have also assessed platelet expression
of P-selectin and the presence of platelet-neutrophil heterotypic
aggregates in STEMI and NSTEMI patients (Figure 1, panel G
and Table 5). At covariance analysis after logarithmic transfor-
mation of data the percentage of platelets expressing P-selectin was
an independent variable (p=0.00016) for platelet-neutrophil
heterotypic aggregates and neutrophil MPO content. Further-
more, the percentage of platelets expressing P-selectin was
inversely correlated with the average neutrophil MPO content
(r=20.75, p,0.001) and directly correlated with the percentage
of neutrophils with complete MPO depletion (r=0.57, p,0.009)
in AMI patients (Figure 1, panel G). Accordingly, the fraction of
platelet-neutrophil heterotypic aggregates correlated inversely with
the average MPO content (r=20.53, p,0.0005) and directly with
the proportion of neutrophils with complete MPO depletion
(r=0.41, p,0.001).
Platelet and neutrophil activation were associated, because the
extent of platelets adhesion (heterotypic aggregates) was signifi-
cantly higher for neutrophils with complete MPO depletion than
with low MPO content. Panels E-F of Figure 1 depict the analysis
of patients samples by confocal microscopy and flow cytometry
simultaneously: only very few adherent platelets were observed in
neutrophils with normal MPO content.
Patients with rheumatoid arthritis and giant cell arteritis showed
a variable proportion of neutrophils with adherent platelets, with
an inverse correlation between the percentage of platelet-
neutrophil heterotypic aggregates and the neutrophil MPO
content (r=0.59, P,0.01). No correlation was found in patients
with ANCA- associated small vessel vasculitis or with severe sepsis.
Platelet P-selectin Expression is Required for MPO
Depletion in Experimental Animals
We have injected purified platelets, either activated or resting,
in the tail vein of C57BL/6 mice. Blood was sampled at 1, 2, 3 and
24 hours after platelet infusion and the neutrophil MPO content
was determined by flow cytometry. One hour after the injection of
activated platelets the percentage of platelets expressing P-selectin
increased from 2.261.3% to 29.061.1% (p,0.001) and
46.065.5% of circulating neutrophils showed complete MPO
depletion (Figure 3). The fraction of platelet-neutrophil hetero-
typic aggregates increased from 5.762.1 to 36.262.3% (p,0.001)
while the neutrophil MPO content decreased from 58.261,6 to
38.961.0 (p,0.001); Figure 3, panel A). No significant change
in any of these parameters was observed in mice injected with
activated platelets from P-sel
2/2 mice (Figure 3, panel B), or
with resting platelets (Figure 3, panel C).
Discussion
Our results indicate that neutrophil activation is substantially
greater in patients with STEMI, compared with those with non
STEMI or unstable angina. Neutrophil activation is associated
with increased neutrophil counts and with a larger fraction of
circulating neutrophils with features reflecting recent origin from
the bone marrow. Of importance, a fraction of neutrophils is not
degranulated in STEMI patients, which may reflect an abnormal
response to activating stimuli or, more likely, a population of
circulating neutrophils never exposed to stimuli restricted within a
specific vascular district. The acute arterial occlusion that is an
hallmark of myocardial infarction could contribute in these
patients to protect neutrophils newly emerged from the bone
marrow, preventing MPO release.
Figure 2. Time course of leukocyte and platelet activation in patients and controls. 36 patients with acute myocardial infarction were
studied before any therapeutic treatment and re-studied at different times on PCI. Results (expressed as mean 6 SEM) were compared with 69
patients with chronic stable angina candidates (CSA) for PCI and 138 healthy donors. Determinations were performed by flow cytometry, with the
exception of troponin I, as described in material and methods. Y axis: serum troponin (Panel A), granulocyte cell counts (panel B), fraction of
circulating neutrophils with complete myeloperoxidase (MPO) depletion (Panel C), average of neutrophil MPO content (Panel D), fraction of platelet
expressing P-selectin (Panel E), the fraction of platelet-neutrophils heterotypic aggregates (Panel F), fraction of platelet-monocyte heterotypic
aggregates (Panel G). *=P,0.05; **=P,0.01 (both respect to CSA and healthy donors) were determined by ANOVA followed Bonferroni test.
doi:10.1371/journal.pone.0039484.g002
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because microbial and endogenous triggers of inflammation are
primarily recognized by innate receptors which are non clonally
distributed on circulating leukocytes. Not surprisingly, a normal
MPO content was observed in only 2% of neutrophils from
patients with severe sepsis. Mobilization of the neutrophil effector
action, and specifically the release of the granule content, could in
principle jeopardize the integrity of the vessel wall [2,3,20,32,33],
and several regulatory feedback mechanisms regulate the extent of
neutrophil activation in the peripheral blood [34]. Accordingly, we
failed to detect the trimodal pattern of MPO expression in any of
the self-sustaining inflammatory conditions investigated, where the
original noxa is likely to be persistent, but possibly expressed at a
lower extent compared to STEMI.
A low neutrophil MPO content was found in patients presenting
with very low levels of troponin I, a well-accepted marker of
myocardial cell death (Table 1, Figure 2A), suggesting that
neutrophil activation is an early event in patients with evolving
AMI. From a pathophysiological perspective, it is intriguing to
speculate whether neutrophil activation may even precede
myocardial injury and may be causally involved in plaque rupture
[2,3,20]. It cannot be excluded that the systemic release of markers
of tissue injury occurs at a later time compared to MPO release.
However, the marked differences in time course raise the
possibility that neutrophil activation associated to myocardial
necrosis may represent a consequence or even a component of the
evolving plaque rupture. Other studies speculated on this tenet
and neutrophil degranulation and the consensual increase of
neutrophil-derived proteases in plasma were found in patients with
unstable angina and acute myocardial infarction.
Tissue necrosis itself could incite neutrophil activation [6] [35].
To address this issue, we have verified the effect of percutaneous
transluminal septal myocardial ablation, a procedure based on the
injection of alcohol into the septal branches of the coronary artery
that feed the enlarged interventricular septum of patients with
hyperthrophic obstructive cardiomyopathy. This procedure results
in the synchronized death of myocardiocytes, with substantial and
swift increase of troponin I blood levels and represents a unique
human model of iatrogenic myocardial necrosis in vivo [24,36]. We
did not detect any MPO content reduction. The result, if
combined with the conserved MPO content of neutrophils after
PCI or acute traumatic fracture of the bone, makes unlikely the
possibility that necrosis per se is sufficient to account for MPO
depletion. Of interest, in none of these circumstances we have
observed increased levels P-selectin or of P-selectin dependent
events, such as heterotypic platelet-leukocyte aggregates.
Moreover, patients with CSA had substantial atherosclerosis of
coronary arteries, but circulating neutrophils had a relatively
normal MPO content. This observation may suggest that
atherosclerosis per se is not directly involved in MPO depletion,
Figure 3. In vivo evidence that circulating activated platelets
cause neutrophil degranulation. Purified platelets from wild type or
Psel
2/2 mice were activated (or not) and injected in the tail vein of wild
type C57BL/6 mice. Platelet activation was achieved with thrombin. The
molecule was then inactivated by addition of hyrudin. Neutrophil
myeloperoxidase content, platelet P-selectin expression and platelet-
neutrophil heterotypic aggregates were assessed by flow cytometry as
described in the Methods. Panel A shows the effect of the in vivo
injection of the buffer used for platelet activation, containing both
thrombin and hyrudin. Blood was retrieved at different times after
injection (hours, x axis) and neutrophils with adherent (filled symbols)
or internalized (grey symbols) platelets were identified by flow
cytometry. .70% of circulating neutrophils were engaged in the
internalization and adhesion of activated, but not resting, platelets after
1 hour. The fraction of circulating neutrophils with internalized and
adherent platelets returned to background levels 24 hours after the
injection. Results are expressed as mean6S.E.M. 5–7 animals were
assessed per each point.
doi:10.1371/journal.pone.0039484.g003
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syndromes.
The persistence of high plasmatic levels of MPO can identify
patients with high risk of complications [32,37]. This study to our
knowledge is the first directly comparing the time courses of
leukocyte activation and myocardial tissue damage. This is of
importance because systemic leukocyte activation is widely
believed to occur as a consequence of myocardial tissue injury
rather than of plaque instability preceding the myocardial
infarction. Our data now indicate that this perception might
underestimate the cross talk between neutrophils and activated
platelets in acute coronary syndromes and well fit with the
previous observations of the widespread activation of neutrophils
across the coronary vascular bed [38].
We have observed a tight correlation between indices of
platelet-neutrophil interaction: the characteristic feature of MPO
content, together with the results obtained in the experimental
animal model, suggest that neutrophil degranulation is due to their
interaction with activated platelets. Indeed, previous experimental
models support the concept that P-selectin is able to induce
neutrophil activation and degranulation [9,10,11,28,39]. The time
course of P-selectin expression observed by us and others
[1,10,11,17] and the evidence that platelet P-selectin is able in vitro
[10,11,28] and in vivo to prompt the degranulation of neutrophil
are in agreement with this model. Our experimental evidences
indicate that a burst of P-selectin expression (such as that induced
in vivo by the injection of activated wild-type but not P-selectin
knock-out platelets) reproduces the extreme and transient neutro-
phil MPO depletion that we have observed in patients with acute
myocardial infarction. These observations may have diagnostic
and pathogenetic implications.
Neutrophil MPO complete depletion occurs when platelets
express P-selectin rather abruptly, like it occurs in patients with
AMI, in which a sudden and transient burst of platelet activation
occurs. This is the scenario that we mimic in the mouse, in which
we directly inject in the blood P-selectin expressing platelets. In
contrast, platelets of patients with unstable angina or with other
systemic inflammatory syndromes are characterized by a persis-
tent, waxing and waning P-selectin expression. This is likely to
recruit adaptive mechanisms that limit the paroxysmal neutrophil
activation and thus protect the integrity of vessel walls. Further
studies are necessary to verify this possibility.
The transient nature of neutrophil activation in patients with
AMI could be explained by rapid loss of P-selectin as a
consequence of active proteolysis [1,39] by the proteases derived
from the neutrophils and by the inhibitory effect of pentraxin 3
released by neutrophils as consequence of activated platelet
adhesion [8,11,40], which has been shown to interfere with
neutrophil functions in vitro and in vivo [41]. Moreover, the
clearance of activated platelets represents a further likely
mechanism involved in the swift termination of neutrophil
activation [7,8,10,26]. The actual contribution of these non-
mutually exclusive mechanisms remains to be established.
Supporting Information
Figure S1 Intracellular MPO content in resting and
stimulated neutrophils assessed by confocal microscopy
and flow cytometry. Whole blood samples from healthy donors
were stimulated as described in material and methods. For
confocal determinations, monoclonal antibodies against MPO
were labeled with Alexa Fluor 488 (green) and DNA labeled with
Hoechst (blue). For flow cytometry, samples were labeled with
mAbs against CD66b (specific for neutrophils) and after
permeabilization with mAbs against MPO.
(TIF)
Table S1 MFI= mean fluorescence intensity.
(DOC)
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